Neurodegenerative Disease Dementia

greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis, Neuropathol Appl Neurobiol, 2002;28:218–27.

18. Queralt R, Ezquerra M, Lleo A, et al., A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer’s disease and marked behavioural disturbances, J Neurol Neurosurg Psychiatry, 2002;72:266–9.

19. Kennedy AM, Newman SK, Frackowiak RS, et al., Chromosome 14 linked familial Alzheimer’s disease. A clinico-pathological study of a single pedigree, Brain, 1995;118(Pt 1):185–205.

20. O’Riordan S, McMonagle P, Janssen JC, et al., Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities, Neurology, 2002;59:1108–10.

21. McKeith IG, Dickson DW, Lowe J, et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 2005;65:1863–72.

22. Emadi S, Barkhordarian H, Wang MS, et al., Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity, J Mol Biol, 2007;368:1132–44.

23. Roman GC, Tatemichi TK, Erkinjuntti T, et al., Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology, 1993;43:250–60.

24. Chui HC, Victoroff JI, Margolin D, et al., Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers, Neurology, 1992;42:473–80.

25. Neary D, Snowden JS, Gustafson L, et al., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology, 1998;51:1546–54.

26. Christodoulou C, Melville P, Scherl WF, et al., Effects of donepezil on memory and cognition in multiple sclerosis, J Neurol Sci, 2006;245:127–36.

27. Okamoto S, Kang YJ, Brechtel CW, et al., HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest, Cell Stem Cell, 2007;1:230–36.

28. Zhao Y, Navia BA, Marra CM, et al., Memantine for AIDS dementia complex: open-label report of ACTG 301, HIV Clin Trials, 2010;11:59–67.

29. Moriyama Y, Muramatsu T, Kato M, et al., Family history of alcoholism and cognitive recovery in subacute withdrawal, Psychiatry Clin Neurosci, 2006;60:85–9.

30. Heinemann U, Zerr I, Demenzen: Pathogenese, neurochemische Diagnostik sowie reversible Demenzsyndrome, Neuroforum, 2007;2:47–54.

31. Gawinecka J, Zerr I, Cerebrospinal fluid biomarkers in human prion diseases, Future Neurol, 2010;5:301–16.

32. Hansson O, Zetterberg H, Buchhave P, et al., Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a

follow-up study, Lancet Neurol, 2006;5:228–34.

33. Kanemaru K, Kameda N, Yamanouchi H, Decreased CSF amyloid beta 42 and normal tau levels in dementia with Lewy bodies, Neurology, 2000;54:1875–6.

34. Mollenhauer B, Bibl M, Trenkwalder C, et al., Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease, J Neural Transm, 2005;112:933–48.

35. Sunderland T, Linker G, Mirza N, et al., Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, 2003;289:2094–2103.

36. Wiltfang J, Esselmann H, Smirnov A, et al., Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Ann Neurol, 2003;54:263–7.

37. Sjogren M, Minthon L, Davidsson P, et al., CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J Neural Transm, 2000;107:563–79.

38. Hulstaert F, Blennow K, Ivanoiu A, et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, 1999;52:1555–62.

39. Lins H, Wichart I, Bancher C, et al., Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus, J Neural Transm, 2004;111: 273–80.

40. Gloeckner SF, Meyne F, Wagner F, et al., Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia, J Alzheimers Dis, 2008;14:17–25.

41. Otto M, Wiltfang J, Tumani H, et al., Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurosci Lett, 1997;225:210–2.

42. Blennow K, Wallin A, Agren H, et al., Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?, Mol Chem Neuropathol, 1995;26:231–45.

43. Green AJ, Harvey RJ, Thompson EJ, et al., Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease, Neurosci Lett, 1999;259:133–5.

44. Mecocci P, Cherubini A, Bregnocchi M, et al., Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?, Alzheimer Dis Assoc Disord, 1998;12:211–4.

45. Grossman M, Farmer J, Leight S, et al., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease, Ann Neurol, 2005;57:721–9.

46. Arai H, Morikawa Y, Higuchi M, et al., Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology, Biochem Biophys Res Commun, 1997;236:262–4.

47. Andreasen N, Minthon L, Davidsson P, et al., Evaluation of CSF-tau and CSF-Abeta 42 as diagnostic markers for Alzheimer disease in clinical practice, Arch Neurol,

2001;58:373–9.

48. Molina L, Touchon J, Herpe M, et al., Tau and apo E in CSF: potential aid for discriminating Alzheimer’s disease from other dementia, Neuroreport, 1999;10:3491–5.

49. Vanmechelen E, Vanderstichele H, Hulstaert F, et al., Cerebrospinal fluid tau and β amyloid 1-42 in dementia disorders, Mech Ageing Dev, 2001;122:2005–11.

50. Gomez-Tortosa E, Gonzalo I, Fanjul S, et al., Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease, Arch Neurol, 2003;60:1218–22.

51. Mollenhauer B, Cepek L, Bibl M, et al., Tau protein, Abeta 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies, Dement Geriatr Cogn Disord, 2005;19:164–70.

52. Kudo T, Mima T, Hashimoto R, et al., Tau protein is a potential biological marker for normal pressure hydrocephalus, Psychiatry Clin Neurosci, 2000;54: 199–202.

53. Sampson EL, Warren JD, Rossor MN, Young onset dementia, Postgrad Med J, 2004;80:125–39.

54. Kelley BJ, Boeve BF, Josephs KA, Young-onset dementia: demographic and etiologic characteristics of 235 patients, Arch Neurol, 2008;65:1502–8.

55. McMurtray A, Clark DG, Christine D, et al., Early-onset dementia: frequency and causes compared to late-onset dementia, Dement Geriatr Cogn Disord, 2006;21:59–64.

56. Brouwers N, Sleegers K, Van Broeckhoven C, Molecular genetics of Alzheimer’s disease: an update, Ann Med, 2008;40:562–83.

57. Butler D, Brussels seeks BSE diagnostic test to screen European cattle, Nature, 1998;395:205–6.

58. Stefanova N, Bucke P, Duerr S, et al., Multiple system atrophy: an update, Lancet Neurol, 2009;8:1172–8.

59. Lippa CF, Duda JE, Grossman M, et al., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers, Neurology, 2007;68:812–19.

60. Selikhova M, Williams DR, Kempster PA, et al., A clinico-pathological study of subtypes in Parkinson’s disease, Brain, 2009;132:2947–57.

61. Walker FO, Huntington’s disease, Lancet, 2007;369: 218–28.

62. Zerr I, Poser S, Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests, APMIS, 2002;110:88–98.

63. Josephs KA, Holton JL, Rossor MN, et al., Neurofilament inclusion body disease: a new proteinopathy?, Brain, 2003;126:2291–2303.

64. Shibuya-Tayoshi S, Tsuchiya K, Seki Y, et al., Presenile dementia mimicking Pick’s disease: an autopsy case of localized amygdala degeneration with character change and emotional disorder, Neuropathology, 2005;25:235–40.

65. Heinemann U, Gloeckner F, Varges D, et al., Differenzialdiagnose rasch progredienter Demenzen, Zeitschrift für Gerontopsychologie und -psychiatrie, 2007;20:17–26.

28

EUROPEAN NEUROLOGICAL REVIEW